Niharika Dixit
@ndonc.bsky.social
Medical oncologist at UCSF @ZSFG, breast cancer, health equity, supportive care, survivorship care, care delivery, health policy.
Reposted by Niharika Dixit
So excited to announce, alongside chairs @drannekatz.bsky.social and Dr. Linda Bosserman, we will be offering an interactive workshop on sexuality after cancer, held in conjunction with #massc25
Stay tuned for more details!
Stay tuned for more details!
January 31, 2025 at 4:34 PM
So excited to announce, alongside chairs @drannekatz.bsky.social and Dr. Linda Bosserman, we will be offering an interactive workshop on sexuality after cancer, held in conjunction with #massc25
Stay tuned for more details!
Stay tuned for more details!
Reposted by Niharika Dixit
The OncoAlert Video Journal: Cancer Statistics 2025 by Rebecca Siegel Et al.
youtu.be/Gd7o17emuRA
The 2025 American Cancer Society report estimates 2,041,910 new cancer cases and 618,120 deaths in the U.S. While cancer mortality has declined since 1991, racial disparities persist.
youtu.be/Gd7o17emuRA
The 2025 American Cancer Society report estimates 2,041,910 new cancer cases and 618,120 deaths in the U.S. While cancer mortality has declined since 1991, racial disparities persist.
OncoAlert Video Journal: Cancer Statistics 2025 out by Rebecca Siegel MPH of American Cancer Society
YouTube video by OncoAlert 360
youtu.be
January 31, 2025 at 1:32 PM
The OncoAlert Video Journal: Cancer Statistics 2025 by Rebecca Siegel Et al.
youtu.be/Gd7o17emuRA
The 2025 American Cancer Society report estimates 2,041,910 new cancer cases and 618,120 deaths in the U.S. While cancer mortality has declined since 1991, racial disparities persist.
youtu.be/Gd7o17emuRA
The 2025 American Cancer Society report estimates 2,041,910 new cancer cases and 618,120 deaths in the U.S. While cancer mortality has declined since 1991, racial disparities persist.
Group medical visits could be a key component of multidisciplinary care for cancer survivors. We summarize existing data on multidisciplinary group medical visits in cancer survivorship and emphasize the need for further research, including evaluation of ongoing initiatives in this space.
Group medical visits in cancer survivorship care: a scoping review
link.springer.com
December 27, 2024 at 4:52 PM
Group medical visits could be a key component of multidisciplinary care for cancer survivors. We summarize existing data on multidisciplinary group medical visits in cancer survivorship and emphasize the need for further research, including evaluation of ongoing initiatives in this space.
Reposted by Niharika Dixit
As an oncologist, I get constant reminders that holidays are joyful & meaningful milestones, but not every yr & not for everyone. If you are with #grief, I hope this will remind you that you belong to something vast & are not alone.
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
Grief Makes Us Time Travelers (Gift Article)
A neuroscientist studying memory, I used to believe time was linear. Then my mother had a stroke.
www.nytimes.com
December 20, 2024 at 5:08 PM
As an oncologist, I get constant reminders that holidays are joyful & meaningful milestones, but not every yr & not for everyone. If you are with #grief, I hope this will remind you that you belong to something vast & are not alone.
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
#MedSky #OncSky #LongCovid
www.nytimes.com/2024/12/20/s...
Reposted by Niharika Dixit
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 4:51 PM
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Registration for our 2025 Annual Meeting is now open! Register before April 23, 2025 for early bird pricing and join us in Seattle, Washington, USA for the preeminent international meeting on supportive care in cancer.
mascc.org/annualmeetin...
#MASCC25 #SuppOnc @oncoalert.bsky.social
mascc.org/annualmeetin...
#MASCC25 #SuppOnc @oncoalert.bsky.social
December 13, 2024 at 5:48 PM
Reposted by Niharika Dixit
What about delayed immune mediated toxicity?
Jacobs et al:
700 pts all stages; 84% TNBC, 74% Early-stage
Incidence: 61% iTox any time; 34% delayed iTox
8.6% with iTox AFTER TREATMENT
4.7% with iTox 1 year AFTER ICI INITIATION
Should we be checking endocrine labs for years after ICI ?
#SABCS24
Jacobs et al:
700 pts all stages; 84% TNBC, 74% Early-stage
Incidence: 61% iTox any time; 34% delayed iTox
8.6% with iTox AFTER TREATMENT
4.7% with iTox 1 year AFTER ICI INITIATION
Should we be checking endocrine labs for years after ICI ?
#SABCS24
December 11, 2024 at 2:17 PM
What about delayed immune mediated toxicity?
Jacobs et al:
700 pts all stages; 84% TNBC, 74% Early-stage
Incidence: 61% iTox any time; 34% delayed iTox
8.6% with iTox AFTER TREATMENT
4.7% with iTox 1 year AFTER ICI INITIATION
Should we be checking endocrine labs for years after ICI ?
#SABCS24
Jacobs et al:
700 pts all stages; 84% TNBC, 74% Early-stage
Incidence: 61% iTox any time; 34% delayed iTox
8.6% with iTox AFTER TREATMENT
4.7% with iTox 1 year AFTER ICI INITIATION
Should we be checking endocrine labs for years after ICI ?
#SABCS24